ACTINOGEN's key Alzheimer's disease trial showed clinical benefit in elderly patients with mild to moderate disease, good safety, and showed a trend of benefit in the general population.

Zhitongcaijing · 2d ago
ACTINOGEN's key Alzheimer's disease trial showed clinical benefit in elderly patients with mild to moderate disease, good safety, and showed a trend of benefit in the general population.